RENX.L
SellHot AirRenalytix Plc · Healthcare · United Kingdom · $48M
5.80p -2.5% · close 7 Oct · scored 9 Oct
Hot Air: Rising on momentum alone: weak business, rich price.
As of 9 Oct 2026, MoatMap's StockRank for Renalytix Plc (RENX.L) is 25/100: Quality 29, Value 24, Momentum 58, ranked against 24,000+ stocks in 35 markets.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT RENALYTIX PLC
Read
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States.
FINANCIAL SUMMARY (GBP)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 2.2M | 2.6M | 1.7M | 2.3M | 0.3% | 2.5M |
| EPS (GBp) | -10.09 | -9.09 | -8.28 | -5.29 | — | -3.00 |
| Shares | 437.0M | 437.0M | 437.0M | 331.2M | -24.2% | — |
| Debt | 9.3M | 9.2M | 6.4M | 6.3M | -12.4% | 4.4M |
| Equity | 23.1M | 5.3M | -6.8M | -5.3M | -77.2% | — |
| Op CF | -34.7M | -25.8M | -22.5M | -13.5M | — | -9.8M |
| Inv CF | -0.5M | 0 | 75.6K | 0 | — | — |
| Fin CF | 19.4M | 12.4M | 7.6M | 12.1M | — | — |
263% above its 52-week low and back above a rising 50-day average.
Swung more than 85% of stocks we rank over the past year (74% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RENX.L are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RENX.L | Renalytix Plc(you) | $48M | 25 | Sell |
| MPAL.L | MedPal AI PLC | $70M | 17 | Strong Sell |
| DXRX.L | Diaceutics PLC | $215M | 52 | Hold |
| OPT.L | Optima Health plc | $354M | 58 | Hold |
| CRW.L | Craneware plc | $477M | 58 | Hold |
| KOO.L | Kooth plc | $82M | 95 | Strong Buy |
| SAR.L | Sareum Holdings plc | $58M | 22 | Sell |
| MREO | Mereo BioPharma Group plc | $54M | 20 | Strong Sell |
| STX.L | Shield Therapeutics plc | $69M | 26 | Sell |
| PXS.L | Provexis plc | $31M | 26 | Sell |
Peer medians: ROE -4.2% · P/E 23.5x · Gross margin 61.0%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.